KALA BIO, Inc. (NASDAQ:KALA – Free Report) shares are scheduled to reverse split on the morning of Monday, November 16th. The 1-30 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, November 15th.
KALA BIO Price Performance
Shares of KALA traded down $0.01 during midday trading on Thursday, hitting $0.16. The stock had a trading volume of 381,307 shares, compared to its average volume of 223,330. The company has a 50 day simple moving average of $0.34 and a two-hundred day simple moving average of $5.67. KALA BIO has a twelve month low of $0.11 and a twelve month high of $95.50. The firm has a market cap of $3.11 million, a price-to-earnings ratio of -0.01 and a beta of -2.19.
KALA BIO (NASDAQ:KALA – Get Free Report) last issued its quarterly earnings results on Wednesday, August 19th. The company reported ($21.32) EPS for the quarter, missing analysts’ consensus estimates of ($6.00) by ($15.32).
Analyst Ratings Changes
Several equities research analysts have commented on KALA shares. Wall Street Zen upgraded KALA BIO from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of KALA BIO in a research report on Monday, September 21st. One analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.
Check Out Our Latest Stock Analysis on KALA
Institutional Trading of KALA BIO
An institutional investor recently bought a new position in KALA BIO stock. BlackRock Inc. purchased a new stake in KALA BIO, Inc. (NASDAQ:KALA – Free Report) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 71,542 shares of the company’s stock, valued at approximately $124,000. BlackRock Inc. owned approximately 0.37% of KALA BIO as of its most recent SEC filing. 24.61% of the stock is currently owned by hedge funds and other institutional investors.
KALA BIO Company Profile
KALA BIO, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare and severe eye diseases. The company is centered on its mesenchymal stem cell secretome platform, which is designed to deliver multiple naturally occurring growth factors and proteins that may support tissue repair and reduce inflammation. KALA BIO’s lead investigational product candidate, KPI-012, is being developed for the treatment of persistent corneal epithelial defects, a condition in which the surface of the cornea does not heal properly.
Further Reading
- Five stocks we like better than KALA BIO
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for KALA BIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KALA BIO and related companies with MarketBeat.com's FREE daily email newsletter.
